This is one of the few sectors where a single announcement\u2014clinical data, FDA progress, or a major partnership\u2014can send a stock soaring 200%, 500%, even 1,000%+ in a matter of months\u2026 sometimes days.<\/strong><\/p>\n\n\n\n But here\u2019s the catch:<\/p>\n\n\n\n \ud83d\udc49 By the time everyone is talking about it, the biggest gains are already gone.<\/p>\n\n\n\n The real opportunity lies in spotting these companies before the crowd catches on.<\/strong><\/p>\n\n\n\n We\u2019ve Seen This Story Before\u2026<\/strong><\/p>\n\n\n\n Over the past few years, we\u2019ve identified several biotech companies before<\/em> their breakout moments.<\/p>\n\n\n\n One standout example was Celcuity (CELC)<\/strong> which we recommended our readers buy last year.<\/p>\n\n\n\n When it was trading around $8 per share<\/strong>, almost no one was paying attention. But behind the scenes, the company was advancing a promising breast cancer program with a clear regulatory pathway.<\/p>\n\n\n\n Then the market caught on.<\/p>\n\n\n CELC surged past $105 per share<\/strong>\u2014a gain of over 1,000% in just a few months.<\/strong><\/p>\n\n\n\n That kind of move doesn\u2019t happen by accident. It happens when science, timing, and market awareness collide.<\/strong><\/p>\n\n\n\n And by then? It\u2019s already too late to get in early.<\/p>\n\n\n\n Why the Next Wave of Biotech Could Be Even Bigger<\/strong><\/p>\n\n\n\n Right now, a powerful shift is happening in medicine\u2014one that could define the next decade of biotech investing:<\/p>\n\n\n\n Stem Cells Are Going Mainstream<\/strong><\/p>\n\n\n\n For years, stem cells were seen as experimental.<\/p>\n\n\n\n Not anymore.<\/p>\n\n\n\n Today, they are already being used in real-world treatments\u2014especially for serious conditions like:<\/p>\n\n\n\n Even more remarkable:<\/p>\n\n\n\n In 2024, the World Health Organization reported another case of HIV remission<\/strong> linked to a stem cell transplant performed during leukemia treatment.<\/p>\n\n\n\n That\u2019s not theory.<\/p>\n\n\n\n That\u2019s reality.<\/p>\n\n\n\n And it signals something important for investors:<\/p>\n\n\n\n \ud83d\udc49 We are moving from research\u2026 to results.<\/strong><\/p>\n\n\n\n Now Add Artificial Intelligence to the Equation<\/strong><\/p>\n\n\n\n If stem cells are the engine\u2026 Artificial Intelligence is the accelerator.<\/strong><\/p>\n\n\n\n AI is rapidly transforming how treatments are developed, tested, and optimized. It\u2019s speeding up discoveries, improving outcomes, and reducing costly trial-and-error.<\/p>\n\n\n\n The companies combining biotech + AI<\/strong> are operating at a completely different level.<\/p>\n\n\n\n And that brings us to a small, under-the-radar company that\u2019s positioning itself right at this intersection:<\/p>\n\n\n\n Noveris Health Sciences (Symbol: NVRS)<\/strong><\/p>\n\n\n\n Trading at roughly $2 per share<\/strong>, NVRS<\/strong> is aiming to build something far bigger than a single biotech product.<\/p>\n\n\n\n It\u2019s developing an integrated platform<\/strong> designed to modernize how regenerative medicine is delivered.<\/p>\n\n\n\n Here\u2019s what makes it stand out:<\/p>\n\n\n\n 1. A Smarter Approach to Treatment<\/strong><\/p>\n\n\n\n Their system uses AI to:<\/p>\n\n\n\n In a field as complex as regenerative medicine, that\u2019s a major advantage.<\/p>\n\n\n\n 2. Multiple Shots on Goal<\/strong><\/p>\n\n\n\n Unlike many biotech companies that rely on a single drug\u2026<\/p>\n\n\n\n NVRS is developing adipose-derived (fat-based) cell therapies<\/strong> with both:<\/p>\n\n\n\n That creates multiple pathways to success<\/strong>, not just one.<\/p>\n\n\n\n 3. A Scalable Foundation<\/strong><\/p>\n\n\n\n The company also controls a proprietary stem cell library<\/strong>, which could become increasingly valuable as demand grows.<\/p>\n\n\n\n Consistency, quality, and scalability are everything in biotech\u2014and this could give them a meaningful edge.<\/p>\n\n\n\n The Opportunity in Front of You<\/strong><\/p>\n\n\n\n Think about this for a moment:<\/p>\n\n\n\n Those opportunities didn\u2019t look obvious at the time.They looked early. Uncertain. Easy to ignore.<\/p>\n\n\n\n Noveris Health Sciences (NVRS) is still flying under the radar. The setup reminds us a lot of our last winner, CELC which delivered upside of over 1,000% to readers who got in when we featured it.<\/strong><\/p>\n\n\n\n At around $2 per share, NVRS represents the kind of early-stage opportunity that biotech investors constantly search for\u2014but rarely buy in time before the surge.<\/span><\/strong><\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n\n\n\n This communication is provided for informational and marketing purposes only. It does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction. The author is not registered as an investment advisor, portfolio manager, or dealer under applicable securities legislation in Canada or any other jurisdiction. The information contained herein does not constitute investment advice, financial advice, or a recommendation to buy or sell any securities. This communication is not tailored to the investment objectives, financial situation, or needs of any specific individual. High-Risk Warning: Investing in publicly traded securities\u2014particularly micro-cap, small-cap, or early-stage companies\u2014involves a high degree of risk, including the potential loss of your entire investment. Such securities may be highly volatile, illiquid, and subject to significant price fluctuations. Conflict of Interest Disclosure: The author currently holds a long position in the securities of the company discussed in this communication, including approximately 50,000 shares, which were acquired in the open market prior to initiating coverage. Accordingly, the author has a direct financial interest in the performance of the company\u2019s stock and this constitutes a material conflict of interest. The author intends to sell shares of the company and may do so at any time, including during or shortly after the publication of this communication, without notice to readers. As a result, the author may benefit from any increase in the market price or trading volume of the securities discussed. No Independent Verification: The information contained herein has been obtained from sources believed to be reliable; however, it has not been independently verified. No representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. Any reliance placed on such information is strictly at the reader\u2019s own risk. Forward-Looking Statements: This communication may contain forward-looking statements, including but not limited to statements regarding future performance, potential returns, regulatory developments, and market opportunities. These statements are based on current expectations, estimates, and projections, and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially. No Liability: To the fullest extent permitted by law, the author and any affiliated parties disclaim any liability whatsoever for any direct, indirect, or consequential loss arising from the use of, or reliance on, this communication. Independent Advice Recommended: Readers are strongly encouraged to conduct their own due diligence and consult with a licensed investment professional before making any investment decisions.<\/p>\n","protected":false},"excerpt":{"rendered":" In the stock market, life-changing gains don\u2019t usually come from slow, predictable industries. They come from breakthrough moments\u2014and nowhere do those happen more often than in biotech. This is one of the few sectors where a single announcement\u2014clinical data, FDA progress, or a major partnership\u2014can send a stock soaring 200%, 500%, even 1,000%+ in a<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[],"ppma_author":[461],"class_list":{"0":"post-5018","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-business"},"yoast_head":"\n![\"\"](\"https:\/\/thebulletinjournal.com\/wp-content\/uploads\/2026\/03\/celc.png\")
<\/figure>\n<\/div>\n\n\n\n
![\"\"](\"https:\/\/thebulletinjournal.com\/wp-content\/uploads\/2026\/03\/lab.jpg\")
<\/figure>\n\n\n\n
\n\n\n\n\n
\n
\n
![\"\"](\"https:\/\/thebulletinjournal.com\/wp-content\/uploads\/2026\/03\/stocksoar.webp\")
<\/figure>\n\n\n\n